BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer

Bryan P. Schneider, Guanglong Jiang, Tarah J. Ballinger, Fei Shen, Christopher Chitambar, Rita Nanda, Carla Falkson, Filipa C. Lynce, Christopher Gallagher, Claudine Isaacs, Marcelo Blaya, Elisavet Paplomata, Radhika Walling, Karen Daily, Reshma Mahtani, Michael A. Thompson, Robert Graham, Maureen E. Cooper, Dean C. Pavlick, Lee A. Albacker, Jeffrey Gregg, Jeffrey P. Solzak, Yu-Hsiang Chen, Casey L. Bales, Erica Cantor, Bradley A. Hancock, Nawal Kassem, Paul Helft, Bert O'Neil, Anna Maria V. Storniolo, Sunil Badve, Kathy D. Miller, Milan Radovich

Open source

DOI: 10.1200/jco.21.01657
Published: 2022-02-01
Container: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1200/jco.21.01657,
  title = {BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer},
  author = {Bryan P. Schneider and Guanglong Jiang and Tarah J. Ballinger and Fei Shen and Christopher Chitambar and Rita Nanda and Carla Falkson and Filipa C. Lynce and Christopher Gallagher and Claudine Isaacs and Marcelo Blaya and Elisavet Paplomata and Radhika Walling and Karen Daily and Reshma Mahtani and Michael A. Thompson and Robert Graham and Maureen E. Cooper and Dean C. Pavlick and Lee A. Albacker and Jeffrey Gregg and Jeffrey P. Solzak and Yu-Hsiang Chen and Casey L. Bales and Erica Cantor and Bradley A. Hancock and Nawal Kassem and Paul Helft and Bert O'Neil and Anna Maria V. Storniolo and Sunil Badve and Kathy D. Miller and Milan Radovich},
  year = {2022},
  journal = {Journal of Clinical Oncology},
  doi = {10.1200/jco.21.01657},
  url = {https://doi.org/10.1200/jco.21.01657}
}

RIS

TY  - JOUR
TI  - BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer
AU  - Bryan P. Schneider
AU  - Guanglong Jiang
AU  - Tarah J. Ballinger
AU  - Fei Shen
AU  - Christopher Chitambar
AU  - Rita Nanda
AU  - Carla Falkson
AU  - Filipa C. Lynce
AU  - Christopher Gallagher
AU  - Claudine Isaacs
AU  - Marcelo Blaya
AU  - Elisavet Paplomata
AU  - Radhika Walling
AU  - Karen Daily
AU  - Reshma Mahtani
AU  - Michael A. Thompson
AU  - Robert Graham
AU  - Maureen E. Cooper
AU  - Dean C. Pavlick
AU  - Lee A. Albacker
AU  - Jeffrey Gregg
AU  - Jeffrey P. Solzak
AU  - Yu-Hsiang Chen
AU  - Casey L. Bales
AU  - Erica Cantor
AU  - Bradley A. Hancock
AU  - Nawal Kassem
AU  - Paul Helft
AU  - Bert O'Neil
AU  - Anna Maria V. Storniolo
AU  - Sunil Badve
AU  - Kathy D. Miller
AU  - Milan Radovich
PY  - 2022
JO  - Journal of Clinical Oncology
DO  - 10.1200/jco.21.01657
UR  - https://doi.org/10.1200/jco.21.01657
ER  -

APA

Schneider, B. P., Jiang, G., Ballinger, T. J., Shen, F., Chitambar, C., Nanda, R., Falkson, C., Lynce, F. C., Gallagher, C., Isaacs, C., Blaya, M., Paplomata, E., Walling, R., Daily, K., Mahtani, R., Thompson, M. A., Graham, R., Cooper, M. E., Pavlick, D. C., Albacker, L. A., Gregg, J., Solzak, J. P., Chen, Y., Bales, C. L., Cantor, E., Hancock, B. A., Kassem, N., Helft, P., O'Neil, B., Storniolo, A. M. V., Badve, S., Miller, K. D., & Radovich, M. (2022). BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.21.01657

Source records

crossref · retrieved 2026-09-25T21:14:55.870Z